MFDS approves new ‘Olumiant Tab,’ rheumatoid arthritis treatment

Published: 2017-12-13 14:01:15

Updated: 2017-12-13 14:01:15

The Ministry of Food and Drug Safety announced the ministry approved the Lilly Korea’s 2 products including ‘Olumiant Tab 2mg(generic name: baricitinib)’ and ‘Olumiant Tab 4mg(generic name: baricitinib)’ as a rheumatoid arthritis treatment on 11 December.

‘Olumiant Tab,’ an selective and reversible JAK1 & JAK2 inhibitor, is a medicine for the treatment of rheumatoid arthritis(including an prev...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.